• 1
    Ringel Y, Drossman DA. Psychosocial aspects of Crohn's disease. Surg Clin North Am 2001; 81: 23152.
  • 2
    Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003; 54: 21626.
  • 3
    Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 58092.
  • 4
    Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003; 54: 295306.
  • 5
    Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003; 54: 31729.
  • 6
    Andrews H, Barczak P, Allan RN. Psychiatric illness in patients with inflammatory bowel disease. Gut 1987; 28: 16004.
  • 7
    Duffy LC, Zielezny MA, Marshall JR, et al. Lag time between stress events and risk of recurrent episodes of inflammatory bowel disease. Epidemiology 1991; 2: 1415.
  • 8
    Duffy LC, Zielezny MA, Marshall JR, et al. Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease. Behav Med 1991; 17: 10110.
  • 9
    North CS, Alpers DH, Helzer JE, Spitznagel EL, Clouse RE. Do life events or depression exacerbate inflammatory bowel disease? A prospective study. Ann Intern Med 1991; 114: 3816.
  • 10
    Garrett JW, Drossman DA. Health status in inflammatory bowel disease. Biological and behavioral considerations. Gastroenterology 1990; 99: 906.
  • 11
    von Wietersheim J, Kohler T, Feiereis H. Relapse-precipitating life events and feelings in patients with inflammatory bowel disease. Psychother Psychosom 1992; 58: 10312.
  • 12
    Greene BR, Blanchard EB, Wan CK. Long-term monitoring of psychosocial stress and symptomatology in inflammatory bowel disease. Behav Res Ther 1994; 32: 21726.
  • 13
    Levenstein S, Prantera C, Varvo V, et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study [see comments]. Am J Gastroenterol 1994; 89: 121925.
  • 14
    Levenstein S, Prantera C, Varvo V, et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000; 95: 121320.
    Direct Link:
  • 15
    Bitton A, Sewitch MJ, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol 2003; 98: 22038.
    Direct Link:
  • 16
    Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004; 66: 7984.
  • 17
    Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997; 32: 101321.
  • 18
    North CS, Alpers DH. A review of studies of psychiatric factors in Crohn's disease: etiologic implications. Ann Clin Psychiatry 1994; 6: 11724.
  • 19
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 20
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 21
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 87685.
  • 22
    Lashner BA. Clinical features, laboratory findings, and course of Crohn's disease. In: Kirsner, JB, ed. Inflammatory Bowel Disease, 5th edn. Chicago, Illinois: W.B. Saunders Company, 2000: 305314.
  • 23
    Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77: 8436.
  • 24
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 41729.
  • 25
    Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 2001; 31: 14650.
  • 26
    Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 70713.
  • 27
    Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 235763.
    Direct Link:
  • 28
    Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 14517.
  • 29
    Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 815.
  • 30
    Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. Validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 60613.
  • 31
    Persoons P, Luyckx K, Fischler B. Psychiatric diagnoses in gastroenterolgy: validation of a self-report instrument (PRIME-MD PHQ), epidemiology and recognition. Gastroenterology 2001; 120: 615.
  • 32
    Association AP. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington: APA, 1994.
  • 33
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 36170.
  • 34
    Taylor G, Bagby R, Parker J. The alexithymia construct. A potential paradigm for psychosomatic medicine. Psychosomatics 1991; 32: 15364.
  • 35
    Porcelli P, Zaka S, Claudio L, Centonze S, Taylor G. Alexithymia in inflammatory bowel disease. Psychother Psychosom 1995; 64: 4953.
  • 36
    Verissimo R, Mota-Cardoso R, Taylor G. Relationships between alexithymia, emotional control and quality of life in patients with inflammatory bowel disease. Psychother Psychosom 1998; 67: 7580.
  • 37
    Bagby R, Parker J, Taylor G. The twenty-item Toronto Alexithymia Scale. II. Convergent, discriminant, and concurrent validity. J Psychosom Res 1994; 38: 3340.
  • 38
    van Sonderen E. Sociale Steun Lijst-Interacties (SSL-I) en Sociale Steun Lijst-Discrepanties (SSL-D). Een handleiding. Groningen: NGC, Rijksuniversteit Groningen, 1993.
  • 39
    Walker EA, Gelfand MD, Gelfand AN, Creed F, Katon WJ. The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease [see comments]. Gen Hosp Psychiatry 1996; 18: 2209.
  • 40
    Katon WJ, Ciechanowski P. Impact of major depression on chronic medical illness. J Psychosom Res 2002; 53: 85963.
  • 41
    Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol 2002; 97: 19949.
    Direct Link:
  • 42
    Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 243345.
  • 43
    Kroenke K, Spitzer RL. Gender differences in the reporting of physical and somatoform symptoms. Psychosom Med 1998; 60: 1505.
  • 44
    Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003; 17: 117.
  • 45
    Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 3709.
  • 46
    Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 2002; 53: 8736.
  • 47
    Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003; 170: 42933.
  • 48
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 21017.
  • 49
    Addolorato G, De Lorenzi G, Abenavoli L, Leggio L, Capristo E, Gasbarrini G. Psychological support counselling improves gluten-free diet compliance in coeliac patients with affective disorders. Aliment Pharmacol Ther 2004; 20: 77782.
  • 50
    Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004; 363: 158997.